NLE Gastrointestinal Nursing — Hepatic, Biliary & Pancreatic DisordersSummary

Five viral hepatitis types are distinguished primarily by **transmission route**—a cornerstone NLE distinction. **Hepatitis A (HAV) and E (HEV)** are transmitted via the **fecal–oral route** (contaminated food, water, poor sanitation); both are typically **acute and self-limiting**, though HEV carries dangerous maternal-fetal transmission and high mortality in pregnancy. **Hepatitis B (HBV), C (HCV), and D (HDV)** are transmitted via **blood and body fluids** (sexual contact, needlestick injury, transfusion, perinatal transmission in HBV). HBV and HCV establish **chronic infection** in a proportion of exposed individuals and are the two leading causes of cirrhosis and hepatocellular carcinoma globally. **Hepatitis D (HDV) requires HBV coinfection to replicate**—it cannot occur alone. **Memory aid: "A and E **Enter** via the **E**nd (fecal–oral); B, C, D come from **B**lood."** In the Philippines, **chronic HBV prevalence is historically ~10% of adults**, making it a major public-health priority; universal **birth-dose HBV vaccination within 24 hours** and **hepatitis B immunoglobulin (HBIG)** for newborns of HBsAg-positive mothers within 12 hours of birth are critical interventions under the Expanded Program on Immunization (EPI).

Acute viral hepatitis progresses through three clinical phases. The **prodromal (pre-icteric) phase** lasts 1–2 weeks: **anorexia, nausea, fatigue, malaise, right-upper-quadrant discomfort, low-grade fever, myalgias**—symptoms that mimic influenza. The **icteric phase** begins when **hyperbilirubinemia rises above ~2–3 mg/dL**: **visible jaundice (icterus) of sclera and skin, dark urine (bilirubinuria), clay/pale stools (decreased bile reaching the intestine), and pruritus** (from bile salt deposition in skin). Right-upper-quadrant tenderness and hepatomegaly are typically present. This phase lasts 4–6 weeks. The **convalescent phase** involves symptom resolution; however, **fatigue may persist for weeks to months**, and some patients report residual malaise. **Laboratory markers: ALT and AST are markedly elevated (often >1,000 IU/L in acute viral hepatitis), with ALT typically exceeding AST—a pattern that distinguishes viral hepatitis from alcoholic hepatitis (where AST > ALT).** Total and conjugated bilirubin rise. **Serologic markers are pathognomonic**: **anti-HAV IgM** indicates acute hepatitis A; **HBsAg (hepatitis B surface antigen)** indicates active HBV infection or carrier state; **anti-HBc IgM** marks acute HBV infection, while **anti-HBs (antibody to surface antigen)** indicates immunity from vaccination or recovery; **anti-HCV** indicates HCV exposure (confirmed by HCV RNA PCR); **anti-HDV** indicates HDV coinfection (requires HBsAg to be present). **RA 9173 Standard 1.1 (Health Promotion)** mandates that nurses understand these markers to counsel patients and contacts appropriately.

**Nursing care for acute viral hepatitis is primarily supportive, as no specific antiviral exists for HAV, HBV, or HEV.** Key interventions: (1) **Activity as tolerated**—encourage rest during the icteric phase but allow gradual mobilization as symptoms improve; (2) **Nutrition: small, frequent, high-calorie, high-carbohydrate meals; moderate protein; low fat** (fat may worsen nausea); (3) **Hydration: encourage oral fluids** or IV if unable to tolerate oral intake; (4) **ABSOLUTE AVOIDANCE of alcohol and hepatotoxic drugs**, especially **acetaminophen/paracetamol** (even at therapeutic doses, the failing liver cannot metabolize it safely); also avoid **sedatives, barbiturates, and NSAIDs** without medical guidance; (5) **Monitor liver function tests and bilirubin trends**—normalization indicates recovery. **Infection control is critical and varies by transmission route**: **HAV and HEV (fecal–oral)** require **contact precautions** plus **standard precautions**; emphasize **hand hygiene after toileting and before eating**; in healthcare facilities, use designated bedpans, and ensure thorough environmental cleaning; **HBV, HCV, HDV (blood/body fluids)** require **standard precautions** including **proper handling of sharps, blood spill cleanup with chlorine-based disinfectant, and safe needle disposal**. **Post-exposure prophylaxis for HBV: unvaccinated or non-responding contacts receive 2 doses of HBIG (500 IU IM) at time of exposure and 1 month later; all contacts should complete the HBV vaccine series.** **Newborns of HBsAg-positive mothers must receive HBIG (100 IU IM) and the first HBV vaccine dose within 12 hours of birth** to prevent perinatal transmission (which carries >90% risk of chronic infection if not prophylaxed). **Under RA 9173, nurses in birth facilities are responsible for ensuring this protocol is completed.**

**Cirrhosis is irreversible, diffuse hepatic fibrosis with nodular regeneration**, replacing functional hepatocytes and disrupting the normal liver architecture. The three leading causes are **(1) chronic hepatitis B, (2) chronic hepatitis C, and (3) alcohol abuse**; in developed nations, **non-alcoholic fatty liver disease (NAFLD)** is increasingly common. **Pathophysiology: as healthy liver tissue is replaced by fibrous scar, hepatic resistance to blood flow increases, causing PORTAL HYPERTENSION** (elevated pressure in the portal vein, normally 5–10 mmHg; >12 mmHg defines portal hypertension). Portal hypertension triggers **splanchnic vasodilation and activation of compensatory neurohumoral mechanisms (renin–angiotensin–aldosterone system, sympathetic nervous system)**, leading to **sodium and water retention, ascites formation, and peripheral edema**. Simultaneously, **loss of functional hepatocytes impairs synthetic function: ↓ albumin (↓ oncotic pressure, worsening ascites/edema), ↓ clotting factors II, V, VII, IX, X (prolonged PT/INR, bleeding risk), ↓ ammonia detoxification (→ hepatic encephalopathy), ↓ glucose homeostasis (hypoglycemia or hyperglycemia)**. **Variceal development**: portal hypertension causes blood to shunt through **portosystemic collaterals—esophageal varices (70% of cirrhotics), gastric varices, hemorrhoids, caput medusae (dilated veins radiating from the umbilicus)**. **Lab hallmarks of cirrhosis: ↓ albumin (<3.5 g/dL, indicating chronic synthetic failure), ↑ bilirubin (direct and indirect), ↑ ammonia (>40–50 mcmol/L), ↑ PT/INR (may be >1.5, indicating coagulopathy), ↓ platelets/thrombocytopenia (<150,000/mm³, from portal hypertension causing splenic sequestration and from ↓ thrombopoietin production), ↓ sodium (<135 mEq/L, from SIADH and water retention).**

**Ascites is the pathologic accumulation of fluid in the peritoneal cavity**, the most common complication of cirrhosis (present in ~50% of cirrhotic patients). **Mechanism: (1) portal hypertension → splanchnic vasodilation → renal sodium and water retention (activation of RAAS and SNS); (2) ↓ albumin (from impaired synthesis) reduces plasma oncotic pressure, allowing fluid transudation into the peritoneum; (3) lymphatic obstruction from liver fibrosis impairs fluid reabsorption.** **Clinical assessment: abdominal distension, weight gain, abdominal discomfort, dyspnea (ascites compressing the diaphragm), and a **positive **fluid wave test** (examiner percusses one flank; a wave transmitted across the abdomen to the opposite flank indicates >1 liter of fluid).** **Diagnostics: **abdominal ultrasound** (imaging of choice, detects >100 mL of fluid); **serum-ascites albumin gradient (SAAG)** — if the difference between serum albumin and ascitic fluid albumin is >1.1 g/dL, the ascites is **portal hypertension-related** (vs. malignancy or infection, which have lower SAAG).** **Nursing Management (aligned with Maslow's physiologic needs):** (1) **Sodium restriction: <2 g/day (88 mEq/day)** — critical to reduce fluid retention; patient education on hidden sodium in processed foods, canned goods, and seasonings is essential; (2) **Diuretics: spironolactone 100–400 mg daily (potassium-sparing aldosterone antagonist) ± furosemide 40–160 mg daily (loop diuretic)**; monitor **serum potassium and creatinine** closely—hypokalemia worsens hepatic encephalopathy; (3) **Daily weights and abdominal girth measurement** — weight gain >0.5 kg/day or girth increase indicates fluid reaccumulation requiring diuretic adjustment; (4) **Fluid restriction to 1–1.5 L/day** if serum sodium <125 mEq/L (severe hyponatremia); (5) **Paracentesis (therapeutic removal of ascitic fluid)** when ascites is **tense** (causing respiratory compromise, pain, or infection risk) or **diagnostic** (to rule out spontaneous bacterial peritonitis); monitor blood pressure and urine output post-paracentesis—rapid fluid removal can cause **paracentesis-induced circulatory dysfunction** (hypotension, acute kidney injury); infuse **human albumin 6–8 g/L of ascites removed** to maintain intravascular volume; (6) **Monitor for complications: spontaneous bacterial peritonitis (fever, acute worsening, abdominal pain), hepatorenal syndrome (rising creatinine despite fluid resuscitation), and hyponatremia.**

**Hepatic encephalopathy (HE) is an altered mental state caused by accumulation of nitrogenous waste products—primarily AMMONIA—that the failing liver cannot detoxify.** In a healthy liver, ammonia (NH3), a neurotoxic byproduct of protein catabolism and bacterial urease activity in the colon, is converted to **urea** via the **urea cycle** and excreted; in cirrhosis, portosystemic shunting and hepatocellular dysfunction bypass and impair this process, allowing ammonia to reach the brain. **Pathophysiology: ammonia crosses the blood–brain barrier, is taken up by astrocytes, converted to glutamine (via glutamine synthetase), which accumulates and causes cellular osmotic stress, leading to astrocytic swelling (cerebral edema), impaired neurotransmission, and reduced cerebral metabolism.** **Clinical grades (West Haven criteria): Grade I = subtle personality changes, sleep disturbance, mild confusion; Grade II = lethargy, personality change, inappropriate behavior, asterixis; Grade III = somnolence, confusion, aggressive behavior; Grade IV = coma.** **Asterixis (flapping tremor)—a key sign**—is demonstrated by asking the patient to hold arms outstretched with palms up; irregular flapping movements indicate encephalopathy. **Fetor hepaticus** (musty, sweet breath odor) results from methyl mercaptan, another toxin. **Precipitating factors (critical to identify and treat): (1) GI bleeding (increased nitrogen load from blood protein), (2) high protein intake, (3) infection (spontaneous bacterial peritonitis, UTI, pneumonia—triggers ammonia release), (4) constipation (ammonia-producing bacteria proliferate), (5) hypokalemia (acidosis favors ammonia absorption by neurons), (6) renal failure, (7) use of sedatives/opioids (depress mental status and respiratory drive—reduce ammonia clearance).** **LACTULOSE: the cornerstone pharmacologic agent.** **Mechanism of action: Lactulose is a synthetic disaccharide poorly absorbed in the small intestine; when it reaches the colon, colonic bacteria ferment it, producing lactic acid and acetic acid, which (1) acidify the colonic lumen (↓ pH to ~5–6), converting ammonia (NH3, lipophilic, readily crosses the blood–brain barrier) to ammonium (NH4+, charged, water-soluble, cannot cross membranes—trapped in the colon); (2) lactulose's osmotic effect produces a laxative action, promoting bowel motility and increasing the contact time of colonic bacteria with ammonia, enhancing ammonia removal.** **Dosing and titration: Initial dose 15–30 mL (or 20–30 g) of lactulose solution orally 2–4 times daily; titrate the dose to achieve **2–3 soft stools per day.** **DO NOT aim for diarrhea or watery stools—excessive diarrhea causes dehydration, electrolyte loss (especially potassium), and prerenal azotemia, all of which WORSEN hepatic encephalopathy by increasing ammonia reabsorption and reducing cerebral perfusion.** If the patient cannot swallow, lactulose may be given as a **rectal retention enema (300 mL lactulose in 700 mL water, retained 30 min) or via NGT.** **Serum ammonia level should be monitored**; levels correlate imperfectly with clinical grade but guide therapy intensity. **Rifaximin 550 mg orally twice daily** is a poorly absorbed, non-systemic antibiotic that reduces ammonia-producing gut bacteria; it is often **added to lactulose** in refractory cases and is considered more effective than neomycin (older agent) for long-term prophylaxis. **Nursing monitoring: assess and document orientation, asterixis presence, sleep pattern, and personality changes each shift; check serum ammonia, electrolytes (especially K+), and renal function regularly; monitor stool frequency and consistency (aim for soft, not liquid); educate patient/family that 2–3 soft stools/day is the target, and report if stools become watery or diarrheal; ensure adequate protein is still given (total restriction is outdated—only transiently restrict in acute episodes; prolonged restriction worsens malnutrition). **Correct precipitating factors: treat infections promptly, correct hypokalemia, avoid opioids/sedatives, maintain bowel regularity.** **RA 9173 NCM Level 3 (Restoration of Health) requires that nurses implement these pharmacologic and non-pharmacologic strategies with precision; overdosing lactulose to diarrhea is a common error that worsens outcomes.**

**Esophageal varices are dilated, thin-walled esophageal veins that develop secondary to portal hypertension.** In cirrhosis, elevated portal pressure (>12 mmHg) forces blood flow to shunt through **portosystemic collaterals**; the esophagus becomes a route for this shunting, and the esophageal submucosa develops **tortuous, aneurysm-like dilations—esophageal varices.** These varices are present in ~50% of compensated cirrhotics and ~80% of decompensated cirrhotics. **Risk of rupture and bleeding correlates with: (1) variceal size, (2) degree of portal hypertension, and (3) presence of "red signs" on endoscopy (red wale markings, cherry-red spots, hematocystic spots).** **Acute Variceal Hemorrhage: Presentation & Management—a MEDICAL EMERGENCY.** **Clinical presentation: sudden onset of **hematemesis (bright red blood or "coffee-ground" vomitus), melena (black tarry stools), abdominal pain, and signs of hypovolemic shock: tachycardia, hypotension, altered mental status, cool clammy skin, oliguria.** Mortality is ~15–30% with modern management, but remains high; this is one of the leading causes of death in cirrhotic patients. **Immediate nursing and medical priorities (aligned with Maslow's physiologic needs—airway, breathing, circulation):** **(1) AIRWAY PROTECTION:** The patient is at **very high aspiration risk** due to hematemesis and possible altered mental status from hypovolemia/encephalopathy. **Place in semi-Fowler's or prone position, keep suction at bedside, prepare for intubation.** If the patient is obtunded, **early intubation is often indicated to protect the airway and allow diagnostic/therapeutic endoscopy.** **(2) VASCULAR ACCESS & FLUID RESUSCITATION:** Establish **two large-bore (18–20 gauge) peripheral IV lines** (or a central line if peripherals cannot be obtained); begin **aggressive fluid resuscitation with normal saline or lactated Ringer's.** **Avoid over-resuscitation:** excessive fluids increase portal pressure, risking further variceal rupture—the target is mean arterial pressure ~65 mmHg (sufficient for organ perfusion, not full "normal" BP). **Blood products: transfuse packed RBCs if Hgb drops below 7–8 g/dL (some guidelines suggest 7–9 g/dL in variceal bleed); aim for Hgb 8–10 g/dL. Give fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) if INR is prolonged (>1.5) to restore clotting factors; cryoprecipitate if fibrinogen <100 mg/dL.** **Avoid over-transfusion of platelets unless count is <20,000/mm³ (transfused platelets are sequestered in the spleen and offer limited benefit in cirrhosis).** **(3) PHARMACOLOGIC VASOCONSTRICTION:** **OCTREOTIDE 50 mcg IV bolus, then 50 mcg/hour continuous infusion** (a somatostatin analog) is the **first-line agent.** It reduces splanchnic and portal blood flow by causing mesenteric vasoconstriction, thereby lowering portal pressure and reducing bleeding into varices. Continue for 2–5 days. **Alternative: terlipressin** (a vasopressin analog; less commonly used in acute settings but effective; causes systemic vasoconstriction and may reduce cardiac output—monitor closely). **Older teaching favored vasopressin alone, but octreotide is now preferred due to fewer systemic side effects.** **(4) ANTIBIOTIC PROPHYLAXIS:** Administer **prophylactic antibiotics**—typically **ceftriaxone 1 g IV every 12 hours** or **norfloxacin 400 mg orally twice daily** (if the patient can swallow)—to reduce bacterial infection (which can precipitate hepatic encephalopathy and worsen outcomes) and to eradicate spontaneous bacterial peritonitis if present. **(5) DEFINITIVE ENDOSCOPIC THERAPY (within 6–12 hours of presentation):** **Endoscopic band ligation (EBL) is now the preferred endoscopic technique** (superior to sclerotherapy in terms of rebleeding rates and mortality). The endoscopist advances an endoscope to visualize esophageal varices and applies rubber bands around them, causing variceal ligation and thrombosis. **EBL is performed urgently in the setting of active bleeding.** Following successful EBL, the patient requires **repeat band ligation sessions at 1–2 week intervals until variceal eradication is achieved.** **(6) RESCUE THERAPY—BALLOON TAMPONADE:** If bleeding continues despite octreotide and endoscopic therapy (rare with modern management), a **Sengstaken-Blakemore tube (3-lumen balloon catheter)** can be inserted. The tube has **gastric and esophageal balloons** that, when inflated, apply direct pressure to bleeding varices. **CRITICAL SAFETY: Keep scissors at the patient's bedside at all times.** If the patient experiences sudden respiratory distress (balloon migrating upward, obstructing the airway), **deflate the balloons or cut the tube immediately** to prevent asphyxiation. Balloon tamponade is **temporary** (max 24 hours to prevent mucosal necrosis) and "buys time" for definitive therapy (e.g., TIPS, liver transplant). **Post-removal monitor for rebleeding (which occurs in ~50% of cases).** **(7) TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS):** If the above measures fail to control bleeding, TIPS (a radiologic procedure creating a shunt between the portal and hepatic veins, bypassing cirrhotic liver) may be considered, though it carries risks of hepatic encephalopathy and shunt thrombosis and is reserved for refractory bleeding. **PREVENTION OF FIRST & RECURRENT VARICES:** - **Non-selective beta-blockers: propranolol 20–160 mg orally twice daily or nadolol 20–160 mg daily.** These **reduce portal pressure** by decreasing cardiac output and splanchnic vasodilation. Beta-blockers reduce the risk of first variceal bleed by ~20–25% and rebleeding by ~40–50%. **Target: reduce resting heart rate by 20–25% or to 55–60 bpm.** Monitor for contraindications (asthma, COPD, bradycardia, hypotension, decompensated heart failure). - **Endoscopic band ligation:** for patients with known large varices or a history of bleeding; repeated until eradication. - **Avoid NSAIDs, aspirin, and other platelet inhibitors** (increase bleeding risk). **Avoid alcohol absolutely.**

**Primary NANDA nursing diagnoses in cirrhosis (aligned with Maslow's hierarchy):** **PHYSIOLOGIC LEVEL (Life-Threatening):*** 1. **Ineffective tissue perfusion (cerebral)** related to hepatic encephalopathy (ammonia accumulation) as evidenced by confusion, asterixis, altered LOC. **Interventions: Monitor orientation, asterixis, fetor hepaticus q4h; initiate/titrate lactulose to 2–3 soft stools/day; monitor serum ammonia; correct precipitating factors (infection, bleeding, hypokalemia); restrict protein only transiently; implement fall precautions (encephalopathic patients are at high fall risk).** 2. **Risk for deficient fluid volume** related to diuretics, vomiting, GI bleeding. **Interventions: Monitor I&O, daily weight, vital signs; assess for signs of dehydration; administer fluids/colloids as prescribed; monitor electrolytes (K+, Na+, Cl-); assess for azotemia (rising creatinine).** 3. **Risk for bleeding** related to ↓ clotting factor synthesis, thrombocytopenia, and esophageal varices. **Interventions: Assess for active bleeding (hematemesis, melena, hematuria, petechiae, easy bruising); use soft toothbrush, electric razor, avoid IM injections, keep nails short; monitor PT/INR, platelet count; have 2 large-bore IVs in place; keep suction at bedside; avoid NSAIDs and aspirin; teach patient/family to report black stools, bloody vomitus, or unusual bruising immediately.** 4. **Risk for infection** (related to ↓ immune function, ascites). **Interventions: Monitor temp q4h; maintain good hygiene; avoid invasive procedures (foley, NGT) unless essential; teach hand hygiene, food safety; administer prophylactic antibiotics if SBP suspected; monitor for signs of SBP (fever, acute worsening, abdominal pain, jaundice).** **SAFETY/PSYCHOSOCIAL LEVEL:** 5. **Excess fluid volume (ascites)** related to portal hypertension and ↓ albumin. **Interventions: Enforce sodium restriction <2 g/day; administer diuretics (spironolactone ± furosemide) as ordered; monitor serum K+ and Cr; document daily weight and abdominal girth; assess for respiratory distress from ascites; educate on fluid/sodium restriction and medication adherence.** 6. **Impaired skin integrity** related to jaundice and edema. **Interventions: Assess skin for breakdown, especially in areas of edema (sacrum, ankles); keep nails short (to prevent scratching); apply cool compresses for pruritus; use gentle soaps, avoid harsh scrubbing; apply moisturizers; provide frequent position changes.** 7. **Anxiety** related to poor prognosis, fear of bleeding. **Interventions: Provide honest, compassionate education about disease and realistic outcomes; encourage support from family/social services; teach relaxation techniques; assess suicide risk (depression is common in end-stage liver disease).** **LOWER MASLOW LEVEL (Self-Care):*** 8. **Imbalanced nutrition (less than body requirements)** related to anorexia, nausea, and restrictions on protein/fat. **Interventions: Provide small, frequent, nutrient-dense meals; avoid fatty foods; administer anti-emetics PRN; involve dietitian; monitor weight trends and albumin; encourage high-calorie supplements.** 9. **Activity intolerance** related to fatigue and hepatic encephalopathy. **Interventions: Encourage activity as tolerated; plan rest periods; assist with ADLs as needed; assess fall risk and implement precautions.** **Maslow Prioritization in Cirrhosis: (1) **Airway/Breathing/Circulation** (hemorrhage, encephalopathy); (2) **Safety** (bleeding precautions, fall prevention, infection prevention); (3) **Fluid/Electrolyte balance** (ascites, diuretics, hypokalemia/hyponatremia); (4) **Comfort & Skin integrity** (jaundice pruritus, edema); (5) **Nutrition & Self-care** (fatigue, anorexia). In acute crises (variceal bleed, encephalopathy), physiologic needs dominate; in stable compensation, ascites management and prevention of rebleeding take priority.**

**Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) are closely related; ~80% of cases of acute cholecystitis are precipitated by stone impaction in the cystic duct.** **Pathophysiology of gallstone formation: bile is normally supersaturated with cholesterol; when bile stasis occurs (obesity, pregnancy, prolonged fasting, certain medications like oral contraceptives and fibrates), cholesterol crystallizes and deposits form stones.** Most gallstones are **cholesterol stones** (~80%), while **pigment stones** (bilirubin-based) form in hemolytic anemia and cirrhosis. **The "5 F's" of risk for cholelithiasis are a classic mnemonic: **Female, Fat (obesity), Forty (age), Fertile (multiparity), and Fair (Caucasian ethnicity)—though gallstones are actually common across races, this mnemonic highlights demographic trends.** **Acute cholecystitis**: occurs when a stone becomes impacted in the cystic duct, blocking bile drainage and causing inflammation, possibly bacterial superinfection. **Clinical manifestations: **sudden onset of severe RIGHT-UPPER-QUADRANT (RUQ) pain, often after eating a FATTY meal (fat stimulates cholecystokinin, which contracts the gallbladder, exacerbating pain).** Pain is **colicky** (crampy, intermittent) and may **radiate to the right shoulder or scapula** (due to visceral-somatic pain referral via the phrenic nerve). Associated symptoms: **nausea, vomiting, fever (if inflamed), mild leukocytosis.** Physical exam: **positive Murphy's sign** (examiner's hand placed under the RUQ; patient takes a deep breath; if pain causes the patient to arrest inspiration as the inflamed gallbladder touches the examiner's hand, the sign is positive—highly specific for cholecystitis). **RUQ tenderness and possible guarding.** **If a stone obstructs the common bile duct (choledocholithiasis), bile cannot drain into the intestine, causing OBSTRUCTIVE JAUNDICE: visible jaundice, dark urine, pale/clay-colored stools, steatorrhea (fatty stools), and significantly elevated alkaline phosphatase and GGT (indicating biliary obstruction).** **Diagnostics:** **(1) **Abdominal ultrasound is the imaging test of choice**—highly sensitive (95%) and specific for detecting gallstones and assessing gallbladder wall thickness (suggesting inflammation); no radiation, patient-friendly. **(2) **Liver function tests: elevated alkaline phosphatase and GGT (cholestasis); elevated bilirubin if obstructed; normal ALT/AST unless coexisting hepatitis.** **(3) **CT scan or MRI if ultrasound is inconclusive or if complications (e.g., perforation) are suspected.** **(4) **HIDA scan (hepatobiliary iminodiacetic acid scan)** can assess cystic duct patency and gallbladder contractility; if the gallbladder does not concentrate isotope, cystic duct obstruction is confirmed.** **Nursing Management & Patient Education:** **(1) Pre-operative (conservative management for asymptomatic stones or acute cholecystitis):** - **Acute phase: NPO (nothing by mouth) to rest the gallbladder and prevent further contraction; IV fluids for hydration.** - **Pain control: opioid analgesia (morphine or hydromorphone); NSAIDs can also be used for symptomatic relief.** - **Anti-emetics (ondansetron, metoclopramide) for nausea/vomiting.** - **Monitor vital signs, I&O, and assess for complications (fever suggesting infection/gangrene, abdominal tenderness suggesting peritonitis, tachycardia suggesting shock).** - **Many acute cholecystitis cases resolve within 24–48 hours with supportive care; the patient can then be discharged and scheduled for elective cholecystectomy.** **(2) Surgical management: **laparoscopic cholecystectomy** is the **gold-standard definitive treatment** (>90% of cases can be done laparoscopically; open conversion is needed if anatomy is unclear or if complications arise).** **Advantages: minimally invasive, shorter hospital stay (often same-day or 1–2 days), faster recovery, lower infection risk.** **Post-operative nursing (laparoscopic cholecystectomy):** - **Monitor vital signs and wound sites (usually 3–4 small incisions); assess for bleeding, infection, or bile leakage.** - **If a **T-tube drain** is placed (less common with modern techniques but still encountered), **monitor drain output (normal is <50–100 mL/day; >500 mL/day or sudden increase suggests bile leak—report immediately).** **Keep the T-tube below the level of the insertion site to prevent reflux; never kink or compress the tube.** **Once output decreases to <20–30 mL/day, clamping and eventual removal occur.** - **Pain control: usually less intense than open surgery; NSAIDs and acetaminophen are often sufficient.** - **Early mobilization (within hours) reduces the risk of thromboembolism and ileus.** - **Diet: typically advance to low-fat diet within 24 hours; full regular diet as tolerated over 1–2 weeks.** - **Discharge teaching: avoid heavy lifting (>4.5 kg/10 lbs) for 2–4 weeks; low-fat diet is recommended initially (fatty food may cause transient diarrhea/loose stools for weeks due to increased bile salts reaching the colon—reassure the patient this is temporary); report fever, increased pain, bleeding, or bile-stained drainage from wounds; plan follow-up in 1–2 weeks.** **(3) Complications: **acute pancreatitis** (if a stone migrates from the cystic duct into the common duct and impacts at the ampulla of Vater); **perforation/gangrene** (rare, high mortality); **ascending cholangitis** (bacterial infection of the bile ducts if obstructed); **biliary dyskinesia** (RUQ pain without stones, sometimes persists post-cholecystectomy).** **Nursing Safety Alert: If a patient has chronic cholecystitis with stones but is asymptomatic, surgery is NOT routinely recommended (surgery carries its own risks).** Exception: **asymptomatic stones in diabetics, immunocompromised patients, or those with calcified gallbladders carry higher complication risk and are often cholecystectomized prophylactically.**

**Acute pancreatitis is acute inflammation of the pancreas caused by AUTODIGESTION—premature activation of pancreatic digestive enzymes within the pancreatic tissue rather than in the duodenum.** The two leading causes are **(1) **gallstones** (~40% of cases, particularly in developed nations) and **(2) **alcohol abuse** (~40%, particularly in men and in lower-income populations).** Other causes: **post-ERCP (endoscopic retrograde cholangiopancreatography), hypertriglyceridemia, drugs (valproic acid, steroids, azathioprine, diuretics, sulfonamides), trauma, hypercalcemia, scorpion venom (rare in developed countries).** **Pathophysiology: in choledocholithiasis, a stone impacted at the ampulla of Vater increases intraductal pressure, forcing pancreatic secretions retrograde into the pancreatic tissue and triggering zymogen (inactive enzyme precursor) activation to active proteases, lipases, and amylases. In alcohol-induced pancreatitis, chronic alcohol impairs antioxidant defenses, increases free radical formation, and causes ductal obstruction via protein plugs and fibrosis, leading to acinar cell injury.** Once enzymes are activated within the tissue, they digest the pancreatic parenchyma, causing edema, inflammation, fat necrosis (lipase digests fat), and hemorrhage. In severe cases, **necrotizing pancreatitis** develops (>30% pancreatic necrosis), carrying high mortality and risk of pancreatic insufficiency. **Clinical Presentation:** - **Severe, boring EPIGASTRIC pain** (often the worst pain a patient has ever experienced) **radiating to the back (due to retroperitoneal inflammation).** Characteristically, **pain is worse when lying supine and relieved by sitting upright or leaning forward with knees flexed to the chest (hunched posture).** This postural relief is **pathognomonic and frequently tested.** - **Nausea, vomiting** (sometimes severe, leading to dehydration and electrolyte loss). - **Fever** (from inflammation; absence does not rule out pancreatitis). - **Abdominal distension, hypoactive or absent bowel sounds** (paralytic ileus common). - **Tachycardia, tachypnea** (from pain and inflammatory mediator release). - **Signs of severe hemorrhagic pancreatitis: **Grey Turner's sign** (blue-gray bruising of the flanks from retroperitoneal bleeding) and **Cullen's sign** (blue-gray bruising around the umbilicus from hemoperitoneum).** These are **rare but highly specific** indicators of severe hemorrhagic pancreatitis with poor prognosis. - **Hypotension and shock** can develop from severe hemorrhage and inflammatory mediator-induced vasodilation. **Diagnostics:** - **Serum amylase: markedly elevated (>3× the upper limit of normal) in acute pancreatitis; rises within 6–12 hours and falls by 3–5 days.** **However, amylase is NOT liver-specific; elevated amylase can also occur with salivary gland disease, GI perforation, or renal failure, so context matters.** - **Serum LIPASE: rises slightly later than amylase but remains elevated for ~7–10 days.** **Lipase is more specific for pancreatic disease** and is the preferred enzyme test. - **Elevated glucose (hyperglycemia from β-cell damage and stress hormone release).** - **↓ Calcium (HYPOCALCEMIA is a critical finding)**: Fat necrosis releases fatty acids that bind calcium (saponification), causing serum calcium to drop. **Severe hypocalcemia (<7 mg/dL) can cause tetany, seizures, and arrhythmias.** **Check for Chvostek's sign** (tap over the facial nerve anterior to the ear; twitching of the upper lip indicates neuromuscular irritability from hypocalcemia) **and Trousseau's sign** (inflate a blood pressure cuff to >systolic pressure for 2–3 min; carpopedal spasm indicates hypocalcemia). **Administer IV calcium gluconate if symptomatic.** - **↑ Triglycerides** (if hypertriglyceridemia is the cause; levels >1,000 mg/dL are diagnostic). - **↑ WBC, ↓ albumin, ↑ bilirubin** (if severe or prolonged). - **Imaging: **CT scan with IV contrast (CT enterography)** is the **gold standard for assessing severity and complications.** It shows pancreatic edema, necrosis, fluid collections, and hemorrhage. **Abdominal ultrasound can detect gallstones** (if that's the cause) **but has limited sensitivity for pancreatic parenchyma. MRCP (magnetic resonance cholangiopancreatography) can assess for choledocholithiasis if suspected.** - **Prognosis: the **APACHE-II score and Ranson's criteria** are used to predict severity. Mortality is ~5% for mild pancreatitis but >20% for necrotizing pancreatitis.** **Nursing Management & Treatment:** **(1) **Pancreatic rest (critical principle).** - **NPO (nothing by mouth) to prevent secretin stimulation of the pancreas.** - **Nasogastric (NG) tube to intermittent low suction if the patient is vomiting or has significant ileus**, preventing abdominal distension and reducing intra-pancreatic pressure. - **Once vomiting ceases and bowel sounds return, gradually advance to soft foods and then regular diet (favoring low-fat foods).** - **Transition to oral feeding as tolerated.** **(2) **Aggressive IV fluid resuscitation.** - **Acute pancreatitis causes **massive fluid sequestration** into the pancreatic tissue and peritoneal cavity (3rd spacing), leading to **hypovolemia and shock** if not replaced.** - **Administer **normal saline or lactated Ringer's** at high rates (100–200 mL/hour initially, titrated to urine output of 0.5–1 mL/kg/hour and to cardiac/renal tolerance).** - **Monitor vital signs, I&O, central venous pressure (if a central line is in place), and renal function (BUN, creatinine, urine output).** - **Correct electrolyte abnormalities: hypocalcemia (IV calcium gluconate if symptomatic), hypomagnesemia, hypokalemia, hypoalbuminemia (can give albumin in severe cases).** **(3) **Pain control.** - **Opioid analgesia (morphine, hydromorphone).** **Classic teaching discouraged morphine (concern about sphincter of Oddi spasm), but current evidence-based practice accepts both morphine and hydromorphone as acceptable.** **Target: adequate pain relief (pain score <4/10) while avoiding excessive sedation that masks deterioration.** - **NSAIDs (e.g., indomethacin) can also be used for symptomatic relief and may reduce inflammatory mediator-induced complications.** **(4) **Nutritional support.** - **In mild pancreatitis, advance to oral diet as tolerated (low-fat).** - **In severe pancreatitis with prolonged NPO status, nutritional support via **jejunal feeding tube (post-pyloric feeding, below the ligament of Treitz) is preferred over TPN** because it maintains gut integrity and may reduce bacterial translocation/infection risk.** **If a feeding tube is not feasible, TPN is an alternative.** **(5) **Monitor for complications.** - **Acute respiratory distress syndrome (ARDS)** from inflammatory mediator release; monitor O2 saturation and respiratory status. - **Acute kidney injury (ARF)** from hypovolemia/shock; monitor Cr, BUN, urine output. - **Pancreatic necrosis and secondary infection** (pancreatic abscess); if fever develops after 5–7 days (or persistent fever), suspect infection—administer antibiotics (carbapenems like meropenem, which penetrate pancreatic tissue well) and consider CT-guided drainage. - **Pancreatic pseudocyst** (collection of pancreatic juice and debris, develops over weeks); large cysts (>6 cm) may require endoscopic or percutaneous drainage. - **Hemorrhagic pancreatitis with ongoing bleeding:** rare, but may require transfusion and occasionally angiographic embolization. - **Disseminated intravascular coagulation (DIC)** in severe cases; monitor PT/INR, platelets, and fibrinogen. - **Multi-organ failure** can develop; ICU care with mechanical ventilation, vasopressor support, and renal replacement therapy may be needed. **(6) **Identify and treat the cause.** - **If **gallstone-induced**, perform **cholecystectomy** (or ERCP for choledocholithiasis) during the acute phase or shortly after recovery, to prevent recurrence.** - **If **alcohol-induced**, provide **alcohol cessation counseling, addiction medicine referral, thiamine and other B vitamin supplementation** (alcohol impairs absorption and metabolism). - **If **drug-induced**, discontinue the offending agent.** **Chronic Pancreatitis: (brief overview)** Results from recurrent or chronic inflammation, leading to progressive pancreatic fibrosis and loss of exocrine/endocrine function. Causes: chronic alcohol (most common), chronic choledocholithiasis, autoimmune, genetic (cystic fibrosis). **Clinical features: chronic epigastric pain, malabsorption/steatorrhea, diabetes mellitus, weight loss.** **Management: (1) **Pancreatic enzyme replacement (pancrelipase 1,000–4,000 IU/kg/meal) taken WITH meals** to digest fat and protein; dose is titrated to stool consistency (goal: 2–3 formed stools/day, not fatty). **(2) Low-fat, high-protein diet.** **(3) Treatment of diabetes.** **(4) Absolute alcohol abstinence.** **(5) Fat-soluble vitamin supplementation (A, D, E, K) if malabsorption is severe.** **(6) Pain control (opioids for refractory pain, but dependency risk is high—consider pancreatic nerve blocks or other interventions if possible).** **(7) Screen for and treat complications: pancreatic cancer (rare but increased risk; vigilance warranted), pseudocysts, ductal obstruction.)**

**Liver function tests (LFTs) are not "tests" of liver function per se, but rather **panels of blood chemistry markers that reflect hepatocellular injury, cholestasis (bile flow obstruction), and synthetic function.** Understanding which test reflects which problem is essential for interpreting clinical presentations and adjusting care. **Hepatocellular Injury Markers:** - **ALT (alanine aminotransferase) and AST (aspartate aminotransferase):** These enzymes are released when hepatocyte membranes are damaged (acute hepatitis, drug toxicity, ischemia). **ALT is more liver-specific** (also found in kidney, heart, muscle, but much lower concentrations); **AST is less specific** (also abundant in skeletal muscle, heart, RBCs). **In acute viral hepatitis, ALT typically exceeds AST** (ALT > AST pattern); **in alcoholic hepatitis, AST > ALT** (because alcohol damages mitochondria, increasing AST release; also, alcohol's metabolites impair ALT synthesis). **Markedly elevated levels (>1,000 IU/L) suggest acute hepatitis, drug toxicity (e.g., acetaminophen overdose), or acute ischemic hepatitis.** Mildly elevated levels (2–5× normal) can occur in cirrhosis, fatty liver, or chronic hepatitis. **Cholestasis Markers (Biliary Obstruction):** - **Alkaline phosphatase (ALP) and GGT (gamma-glutamyl transferase):** These enzymes are released from hepatocyte membranes and bile duct epithelium in response to obstruction or bile accumulation. **Both rise significantly in biliary obstruction (gallstone in common bile duct, pancreatic cancer compressing the duct, cirrhotic strictures).** **ALP also rises in bone disease** (osteoblast activity); **GGT is more liver-specific.** - **Bilirubin (total and direct/conjugated):** Normally, the liver takes up unconjugated bilirubin from blood, conjugates it with glucuronic acid, and excretes it into bile. **In obstruction (e.g., gallstone), conjugated bilirubin backs up into blood, causing jaundice.** **In hemolytic anemia, excessive unconjugated bilirubin is produced and exceeds the liver's conjugation capacity, causing unconjugated hyperbilirubinemia without jaundice (in early stages).** **In viral hepatitis (early), ALT/AST are markedly elevated, but bilirubin rises more gradually**; **in obstruction, ALP rises first, then bilirubin.** **Synthetic Function Markers (Liver's Ability to Synthesize Proteins):** - **Albumin:** The liver synthesizes nearly all plasma albumin. **Normal albumin is 3.5–5.5 g/dL.** **In chronic liver disease (cirrhosis), albumin drops significantly** (<3.0 g/dL indicates severe dysfunction), because the liver cannot produce enough. **Albumin has a long half-life (~20 days), so it falls slowly; acute hepatitis does not significantly lower albumin.** **Low albumin reflects chronic disease and predicts poor prognosis.** Clinically, **↓ albumin contributes to ascites (↓ oncotic pressure) and peripheral edema.** - **Prothrombin time (PT) and INR (international normalized ratio):** The liver synthesizes all coagulation factors except factor VIII (platelet-derived). **In chronic cirrhosis, factors II, V, VII, IX, X synthesis declines, prolonging PT/INR.** **PT/INR elevation in the setting of acute hepatitis suggests very severe injury (fulminant hepatic failure).** **Unlike albumin, PT can change acutely (half-life of factors is hours to days), so it reflects acute as well as chronic dysfunction.** **INR >1.5 generally indicates clinically significant coagulopathy and bleeding risk.** - **Ammonia:** The liver converts ammonia (from protein catabolism and bacterial urease) to urea via the urea cycle. **Normal ammonia is <40–50 mcmol/L.** **In cirrhosis, ammonia accumulates and correlates with hepatic encephalopathy risk**, though the correlation is imperfect (some encephalopathic patients have near-normal ammonia; some with high ammonia are asymptomatic). **Ammonia monitoring guides lactulose dosing.** **Platelet Count:** - **Thrombocytopenia (<150,000/mm³)** is common in cirrhosis due to **(1) bone marrow suppression from alcohol or chronic disease, (2) splenomegaly from portal hypertension (splenic sequestration of platelets), and (3) ↓ thrombopoietin synthesis.** **Platelet count <20,000/mm³ warrants transfusion** (unless contraindicated); **20,000–50,000/mm³ requires monitoring and transfusion if bleeding occurs; >50,000/mm³ rarely requires transfusion except if undergoing invasive procedures.** **Pattern Recognition for NLE:** - **Acute viral hepatitis: ↑ ALT (>↑ AST), ↑ bilirubin, normal/near-normal albumin, normal/near-normal PT (unless fulminant).** - **Biliary obstruction (stone/tumor): ↑ ALP, ↑ GGT, ↑ direct bilirubin, normal/mildly ↑ ALT/AST** (unless there's coexisting pancreatitis). - **Alcoholic hepatitis: ↑ AST (>↑ ALT), ↑ GGT, ↑ bilirubin, often ↓ albumin (if chronic), ↑ PT/INR.** - **Cirrhosis (any cause): variable ALT/AST (often only mildly ↑, because there's fibrosis not acute injury), ↓ albumin (hallmark of chronicity), ↑ PT/INR, ↓ platelets, ↑ ammonia, ↑ bilirubin.** **In end-stage cirrhosis, even ALT/AST may normalize (few functioning hepatocytes left to release enzymes).** **Clinical Application:** If a patient presents with jaundice + abdominal pain + markedly elevated ALP/GGT, suspect **biliary obstruction** and order ultrasound/MRCP. If jaundice + markedly elevated ALT/AST + no abdominal pain, suspect **acute hepatitis** and check serologies. If jaundice + ↓ albumin + ↑ PT/INR, suspect **cirrhosis** and assess for complications.**

**Hepatitis B is endemic in the Philippines, with historically ~10% chronic prevalence in the adult population—one of the highest burdens in the Western Pacific region.** This makes HBV vaccination and post-exposure management **not optional but mandatory public-health nursing practice.** **Under RA 9173 and the Philippine Expanded Program on Immunization (EPI), hepatitis B vaccination is:** **(1) UNIVERSAL BIRTH-DOSE VACCINATION:** All newborns receive the **first dose of HBV vaccine within 24 hours of birth** (ideally, within 12 hours) **regardless of the mother's HBsAg status.** This initial birth dose primes the immune system and provides partial protection during the neonatal period. The series is then completed at 1, 2.5, and 12 months of age (standard EPI schedule). **Rationale: perinatal transmission is highly efficient** (~90% of infected infants develop chronic HBV infection, leading to cirrhosis and liver cancer in adulthood); **delaying the first dose increases transmission risk.** **(2) ANTENATAL HBsAg SCREENING:** All pregnant women should be screened for HBsAg antepartum. **If positive, she is a high-risk case for transmission to the neonate.** **Infants born to HBsAg-positive mothers require:** - **Hepatitis B immunoglobulin (HBIG) 100–200 IU IM within 12 hours of birth** (standard dose in PH is 100 IU IM). HBIG provides immediate passive immunity (antibodies) that neutralize any HBsAg-positive blood/fluid encountered during delivery. - **The HBV vaccine series as above** (birth dose within 12 hours + completing series).** Combined HBIG + vaccine is ~95% effective at preventing perinatal transmission; neither alone is sufficient.** - **The infant should be tested for anti-HBs and HBsAg at 9–12 months post-vaccination to confirm seroconversion (anti-HBs >10 IU/mL indicates protective immunity).** **(3) OCCUPATIONAL POST-EXPOSURE PROPHYLAXIS (for healthcare workers or others with needlestick/exposure):** - **Unvaccinated or non-responders (anti-HBs <10 IU/mL post-vaccination):** Administer **HBIG 500 IU IM at time of exposure** (ideally within 24 hours, effective up to 7 days post-exposure) **and repeat at 1 month.** Simultaneously, begin or complete the HBV vaccine series. - **Vaccinated responders (anti-HBs >10 IU/mL):** No HBIG needed; verify HBsAg is negative in the source (if positive and the exposed person's anti-HBs is <10 IU/mL, administer HBIG and a booster vaccine dose). **(4) VACCINE RESPONSE & TIMING:** HBV vaccine (Engerix-B, Recombivax HB) requires intramuscular injection (not IV or SC, which are less immunogenic). **Standard schedule: 0, 1, 6 months or 0, 1, 2, 12 months depending on the product and protocol.** **Anti-HBs testing 1–2 months after the series completion confirms protection.** ~95% of healthy vaccinees respond; the elderly, immunocompromised, or those with chronic kidney disease/diabetes may have lower response rates and may require higher doses or additional doses. **(5) PREVENTION BEYOND VACCINATION:** - **Safe injection practices: single-use syringes, proper sharps disposal, never recap needles, use safety-engineered devices.** - **Blood bank screening: all units must be tested for HBsAg.** - **Infection control: standard precautions in all healthcare settings.** - **Sexual transmission prevention: condoms, partner vaccination.** - **Household contact management: non-sharing of razors, toothbrushes, eating utensils.** **RA 9173 Professional Obligations:** Nurses in maternal-child health settings must **ensure the birth-dose vaccine and HBIG (if indicated) are administered within the critical window.** Nurses in occupational health must **maintain hepatitis B vaccination records, assess vaccination status in all new hires, and manage post-exposure protocols immediately.** Nurses in primary care must **identify HBsAg-positive individuals, counsel on transmission prevention, and coordinate vaccination of household/sexual contacts.** Failure to implement these measures is a breach of the professional standard of care.

Chronic HBV or HCV infection drives progressive fibrosis → cirrhosis in 10–30% of chronically infected individuals over decades. The liver's synthetic function declines; portal hypertension develops; complications (ascites, varices, encephalopathy) emerge. This progression underscores the **importance of early HBV/HCV detection and antiviral therapy** to prevent cirrhosis. In the Philippine context, universal HBV vaccination prevents this trajectory in 95% of vaccinated individuals.

Cirrhosis causes portal hypertension, which triggers a cascade: **(1) splanchnic vasodilation → sodium/water retention → ascites; (2) esophageal varices (portosystemic shunting); (3) hepatic encephalopathy (ammonia shunting past the liver); (4) splenomegaly → thrombocytopenia; (5) renal dysfunction (hepatorenal syndrome).** Each complication requires targeted intervention (diuretics/Na+ restriction for ascites, octreotide/band ligation for varices, lactulose for encephalopathy). Understanding portal hypertension as the **common root pathophysiology** unifies the management approach.

Cirrhosis impairs synthesis of **clotting factors II, V, VII, IX, X** (produced by the liver) → prolonged PT/INR; additionally, **thrombocytopenia from splenomegaly/↓ thrombopoietin synthesis** compounds bleeding risk. **Esophageal varices, impaired platelet function, and ↑ fibrinolysis add further risk.** This multifactorial coagulopathy necessitates aggressive **bleeding precautions (soft toothbrush, electric razor, no IM injections)** and careful **monitoring of PT/INR and platelets.** Correction of coagulopathy before invasive procedures (paracentesis, EBL) is critical.

Ascites from portal hypertension + ↓ albumin results in **relative hypovolemia** and triggers **renal vasoconstriction** (renin–angiotensin–aldosterone activation). In severe cases, **renal blood flow declines disproportionately, causing acute kidney injury despite normal or low urine output**—**hepatorenal syndrome (HRS).** HRS is a grave complication with high mortality. Prevention involves **judicious fluid resuscitation, avoiding over-diuresis (which worsens hypovolemia), and early recognition of rising creatinine despite ascites management.** Management of HRS is complex: vasoconstrictors (terlipressin), albumin infusion, and ultimately liver transplantation.

The liver normally detoxifies ammonia (from protein catabolism and bacterial urease) via the urea cycle. In cirrhosis, **portosystemic shunting and hepatocyte dysfunction impair ammonia detoxification.** Ammonia accumulates, crosses the blood–brain barrier, and is taken up by astrocytes → **glutamine accumulation, astrocytic swelling, cerebral edema, and impaired neurotransmission.** **Lactulose lowers ammonia by converting NH3 (lipophilic, crosses BBB) to NH4+ (charged, cannot cross), then excreting it via stool.** This mechanistic understanding explains **why overdosing lactulose to diarrhea worsens encephalopathy** (diarrhea causes dehydration + hypokalemia + prerenal azotemia, all of which increase ammonia reabsorption). **Similarly, precipitating factors (GI bleeding increasing protein load, infection increasing ammonia release, constipation prolonging ammonia absorption) are all mechanistically understandable and targetable.**

**Choledocholithiasis (stone in common bile duct)** obstructs the ampulla of Vater → **↑ intraductal pancreatic pressure → retrograde flow of pancreatic secretions into pancreatic tissue → premature enzyme activation → acute pancreatitis.** This is the **leading cause of acute pancreatitis in developed nations** (~40% of cases). The nursing implication: **recognition that acute pancreatitis in a patient with known gallstones or biliary colic is likely stone-induced, and definitive treatment requires cholecystectomy (or ERCP to extract the stone) to prevent recurrence.** Many patients have recurrent pancreatitis if the gallbladder is not removed.

Chronic inflammation → progressive pancreatic fibrosis → loss of acinar tissue (exocrine function) and islet cells (endocrine function). **Exocrine insufficiency → ↓ digestive enzyme secretion → malabsorption, steatorrhea, and nutritional deficiencies.** **Endocrine insufficiency → diabetes mellitus.** **Management: pancreatic enzyme replacement (pancrelipase WITH meals) restores digestion; insulin manages diabetes; fat-soluble vitamin supplementation (A, D, E, K) corrects deficiencies.** The need for **lifelong enzyme supplementation** reflects the irreversibility of pancreatic damage and underscores the importance of **alcohol cessation early** to prevent this trajectory.

**Acute hepatitis: ↑ ALT/AST (hepatocyte injury) correlate with symptom severity and determine recovery timeline; ↑ PT/INR only if fulminant (poor sign).** **Chronic liver disease (cirrhosis): ↓ albumin and ↑ PT/INR (synthetic dysfunction) are the **most powerful prognostic markers**; ALT/AST may be only mildly ↑ or even normal (fibrosis, not injury, is the dominant process).** **In acute decompensation: ↑ ammonia guides lactulose dosing; ↑ bilirubin reflects cholestasis/synthetic failure; ↓ Na+ (SIADH, fluid overload) worsens encephalopathy.** Understanding these relationships allows nurses to **interpret trends** (Is the patient improving—falling bilirubin, rising albumin? Or declining—rising PT/INR, ↑ ammonia?) **and adjust interventions accordingly.**

**HBV vaccination (anti-HBs >10 IU/mL) prevents chronic infection in ~95% of vaccinees.** **If vaccinated person has a known exposure to HBsAg+, checking anti-HBs immediately post-exposure guides prophylaxis: if anti-HBs >10 IU/mL, no HBIG needed (immunity intact); if <10 IU/mL or non-responder, HBIG + vaccine booster are needed.** **For an unvaccinated person exposed to HBsAg+, HBIG (500 IU IM) provides immediate passive immunity; vaccine series begins to establish active immunity.** **In newborns, HBIG + vaccine (birth dose) together achieve ~95% protection against perinatal transmission; neither alone is sufficient.** This cascade of decisions reflects the **pharmacologic and immunologic principles underlying HBV post-exposure management**, a cornerstone of occupational and perinatal nursing practice.